Lecithin retinol acyltransferase as a potential prognostic marker for malignant melanoma

9Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Metabolism inside cells differs between cancer and normal cells. Because disturbance of vitamin A metabolism might be important, we investigated expression of the enzymes lecithin retinol acyltransferase (LRAT) and RPE65 by immunohistochemistry in melanoma metastases and melanocytic nevi. Semiquantitative evaluation of this expression revealed downregulated expression of RPE65 in malignant melanoma compared with benign melanocytic nevi (P < 0.001). In contrast, expression of LRAT was not significantly different (P = 0.339). High LRAT expression in melanoma metastases was inversely correlated with patient survival; Kaplan-Meier analysis revealed earlier melanoma-related death (P = 0.003). Expression of LRAT might, therefore, be a prognostic marker of the clinical course of melanoma. © 2013 John Wiley & Sons A/S.

Cite

CITATION STYLE

APA

Hassel, J. C., Amann, P. M., Schadendorf, D., Eichmüller, S. B., Nagler, M., & Bazhin, A. V. (2013). Lecithin retinol acyltransferase as a potential prognostic marker for malignant melanoma. Experimental Dermatology, 22(11), 757–759. https://doi.org/10.1111/exd.12236

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free